搜索结果：biotechnology

Biotechnology Industry 5.0 is advancing with the integration of cutting-edge technologies like Machine Learning (ML), the Internet Of Things (IoT), and cloud computing. It is no surprise that an industry that utilizes data from customers and can alter their lives is a target of a variety of attacks. This chapter provides a perspective of how Machine Learning Security Operations (MLSecOps) can help secure the biotechnology Industry 5.0. The chapter provides an analysis of the threats in the biotechnology Industry 5.0 and how ML algorithms can help secure with industry best practices. This chapter explores the scope of MLSecOps in the biotechnology Industry 5.0, highlighting how crucial it is to comply with current regulatory frameworks. With biotechnology Industry 5.0 developing innovative solutions in healthcare, supply chain management, biomanufacturing, pharmaceuticals sectors, and more, the chapter also discusses the MLSecOps best practices that industry and enterprises should follow while also considering ethical responsibilities. Overall, the chapter provides a discussion of how to integrate MLSecOps into the design, deployment, and regulation of the processes in biotechnology

A new class of software systems is transforming investment analysis. Large language model agents assembled into collaborative team structures including analysts, researchers, and risk managers are increasingly deployed across financial markets. Yet current multi-agent frameworks share a critical limitation: they rely on the foundational assumption that companies can be valued through traditional cash flows. This paradigm fails in clinical-stage biotechnology, where enterprise value depends entirely on binary scientific and regulatory milestones. To bridge this gap, this paper introduces a specialized multi-agent framework. Its valuation layer translates qualitative scientific judgment into defensible valuations for pre-revenue assets; its cross-market coordination layer reconciles pricing across international venues simultaneously; and its conflict-fusion mechanism systematically arbitrates between bullish scientific conviction and cautious regulatory constraints in a domain-specific manner. Crucially, the architecture is not a speculative design: it encodes a method the author first executed by hand as sole portfolio manager of China's first dedicated cross-border biotechnology fu

In the past few decades, the life sciences have experienced an unprecedented accumulation of data, ranging from genomic sequences and proteomic profiles to heavy-content imaging, clinical assays, and commercial biological products for research. Traditional static databases have been invaluable in providing standardized and structured information. However, they fall short when it comes to facilitating exploratory data interrogation, real-time query, multidimensional comparison and dynamic visualization. Integrated data-driven research environments aiming at supporting user-driven data queries and visualization offer promising new avenues for making the best use of the vast and heterogeneous data streams collected in biological research. This perspective article discusses the potential of interactive and integrated frameworks, highlighting the importance of implementing this model in biotechnology research, while going through the state-of-the-art in database design, technical choices behind modern data management systems, and emerging needs in multidisciplinary research. Special attention is given to data interrogation strategies, user interface design, and comparative analysis capa

Nanoinformatics is a novel, rapidly growing area of research that involves the application of computational techniques to several aspects of research in the field of nanotechnology, especially concerned its application to biotechnology. This reviews aims to explore, summarize and categorize recent publications on the subject.

Selected applications of novel techniques in Agricultural Biotechnology, Health Food formulations and Medical Biotechnology are being reviewed with the aim of unraveling future developments and policy changes that are likely to open new niches for Biotechnology and prevent the shrinking or closing the existing ones. Amongst the selected novel techniques with applications to both Agricultural and Medical Biotechnology are: immobilized bacterial cells and enzymes, microencapsulation and liposome production, genetic manipulation of microorganisms, development of novel vaccines from plants, epigenomics of mammalian cells and organisms, as well as biocomputational tools for molecular modeling related to disease and Bioinformatics. Both fundamental and applied aspects of the emerging new techniques are being discussed in relation to their anticipated impact on future biotechnology applications together with policy changes that are needed for continued success in both Agricultural and Medical Biotechnology. Several novel techniques are illustrated in an attempt to convey the most representative and powerful tools that are currently being developed for both immediate and long term applicat

Digital twins (DTs) are revolutionizing the biotechnology industry by enabling sophisticated digital representations of biological assets, microorganisms, drug development processes, and digital health applications. However, digital twinning at micro and nano scales, particularly in modeling complex entities like bacteria, presents significant challenges in terms of requiring advanced Internet of Things (IoT) infrastructure and computing approaches to achieve enhanced accuracy and scalability. In this work, we propose a novel framework that integrates the Internet of Bio-Nano Things (IoBNT) with advanced machine learning techniques, specifically convolutional neural networks (CNN) and federated learning (FL), to effectively tackle the identified challenges. Within our framework, IoBNT devices are deployed to gather image-based biological data across various physical environments, leveraging the strong capabilities of CNNs for robust machine vision and pattern recognition. Subsequently, FL is utilized to aggregate insights from these disparate data sources, creating a refined global model that continually enhances accuracy and predictive reliability, which is crucial for the effecti

The biotechnology industry poses challenges and possibilities for startups and small businesses. It is characterized by high charges and complex policies, making it difficult for such agencies to set up themselves. However, it additionally offers avenues for innovation and increase. This paper delves into powerful techniques that can be a resource in managing biotechnology innovation, which includes partnerships, highbrow assets improvement, virtual technologies, customer engagement, and government investment. These strategies are important for fulfillment in an industry that is constantly evolving. By embracing agility and area of interest focus, startups and small companies can successfully compete in this dynamic discipline.

Microfluidic droplet screens serve as an innovative platform for high-throughput biotechnology, enabling significant advancements in discovery, product optimization, and analysis. This review sheds light on the emerging trend of interaction assays in microfluidic droplets, underscoring the unique suitability of droplets for these applications. Encompassing a diverse range of biological entities such as antibodies, enzymes, DNA, RNA, various microbial and mammalian cell types, drugs, and other molecules, these assays demonstrate their versatility and scope. Recent methodological breakthroughs have escalated these screens to novel scales of bioanalysis and biotechnological product design. Moreover, we highlight pioneering advancements that extend droplet-based screens into new domains: cargo delivery within human bodies, application of synthetic gene circuits in natural environments, 3D-printing, and the development of droplet structures responsive to environmental signals. The potential of this field is profound and only set to increase.

This study examines the presence of the day-of-the-week effect on daily returns of biotechnology stocks over a 16-year period from January 2002 to December 2015. Using daily returns from the NASDAQ Biotechnology Index (NBI), we find that the stock returns were the lowest on Mondays, and compared to the Mondays the stock returns were significantly higher on Wednesdays, Thursdays, and Fridays. Moreover, the results from using the asymmetric GARCH processes reveal that momentum and small-firm effect were positively associated with the market risk-adjusted returns of the biotechnology stocks during this period. The findings of our study suggest that active portfolio managers need to consider the day of the week, momentum, and small-firm effect when making trading decisions for biotechnology stocks.

The number of people able to end Earth's technical civilization has heretofore been small. Emerging dual-use technologies, such as biotechnology, may give similar power to thousands or millions of individuals. To quantitatively investigate the ramifications of such a marked shift on the survival of both terrestrial and extraterrestrial technical civilizations, this paper presents a two-parameter model for civilizational lifespans, i.e. the quantity $L$ in Drake's equation for the number of communicating extraterrestrial civilizations. One parameter characterizes the population lethality of a civilization's biotechnology and the other characterizes the civilization's psychosociology. $L$ is demonstrated to be less than the inverse of the product of these two parameters. Using empiric data from Pubmed to inform the biotechnology parameter, the model predicts human civilization's median survival time as decades to centuries, even with optimistic psychosociological parameter values, thereby positioning biotechnology as a proximate threat to human civilization. For an ensemble of civilizations having some median calculated survival time, the model predicts that, after 80 times that dura

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated proteins (Cas) constitute a multi-functional, constantly evolving immune system in bacteria and archaea cells. A heritable, molecular memory is generated of phage, plasmids, or other mobile genetic elements that attempt to attack the cell. This memory is used to recognize and interfere with subsequent invasions from the same genetic elements. This versatile prokaryotic tool has also been used to advance applications in biotechnology. Here we review a large body of CRISPR-Cas research to explore themes of evolution and selection, population dynamics, horizontal gene transfer, specific and cross-reactive interactions, cost and regulation, non-immunological CRISPR functions that boost host cell robustness, as well as applicable mechanisms for efficient and specific genetic engineering. We offer future directions that can be addressed by the physics community. Physical understanding of the CRISPR-Cas system will advance uses in biotechnology, such as developing cell lines and animal models, cell labeling and information storage, combatting antibiotic resistance, and human therapeutics.

In keeping with the definition that biotechnology is really no more than a name given to a set of techniques and processes, the authors apply some set of fuzzy techniques to chemical industry problems such as finding the proper proportion of raw mix to control pollution, to study flow rates, to find out the better quality of products. We use fuzzy control theory, fuzzy neural networks, fuzzy relational equations, genetic algorithms to these problems for solutions. When the solution to the problem can have certain concepts or attributes as indeterminate, the only model that can tackle such a situation is the neutrosophic model. The authors have also used these models in this book to study the use of biotechnology in chemical industries. This book has six chapters. First chapter gives a brief description of biotechnology. Second chapter deals will proper proportion of mix of raw materials in cement industries to minimize pollution using fuzzy control theory. Chapter three gives the method of determination of temperature set point for crude oil in oil refineries. Chapter four studies the flow rates in chemical industries using fuzzy neutral networks. Chapter five gives the method of m

In the domain of technology startups, biotechnology has often been considered as specific. Their unique technology content, the type of founders and managers they have, the amount of venture capital they raise, the time it takes them to reach an exit as well as the technology clusters they belong to are seen as such unique features. Based on extensive research from new databases, the author claims that the biotechnology startups are not as different as it might have been claimed: the amount of venture capital raised, the time to exit, their geography are indeed similar and even their equity structure to founders and managers have similarities. The differences still exist, for example the experience of the founders, the revenue and profit level at exit.

Driven by advancements in high-throughput biological technologies and the growing number of sequenced genomes, the construction of in silico models at the genome scale has provided powerful tools to investigate a vast array of biological systems and applications. Here, we review comprehensively the uses of such models in industrial and medical biotechnology, including biofuel generation, food production, and drug development. While the use of in silico models is still in its early stages for delivering to industry, significant initial successes have been achieved. For the cases presented here, genome-scale models predict engineering strategies to enhance properties of interest in an organism or to inhibit harmful mechanisms of pathogens. Going forward, genome-scale in silico models promise to extend their application and analysis scope to become a transformative tool in biotechnology.